News & Events

Neuros Medical Enrolls First Patients in Pivotal Study for Post-Amputation Pain

Cleveland, OH, January 28, 2015– Neuros Medical, Inc., a medical device company, announced it has enrolled the first patients in its pivotal clinical trial to evaluate the Company’s patented Altius® System High Frequency Nerve Block technology for the management of intractable limb pain of amputees. The prospective, randomized, controlled pivotal clinical trial will consist of up to 130 patients at 15 institutions to evaluate the safety and efficacy of Neuros Medical’s Altius System. When completed, the results will support a PreMarket...

read more

Big year: RiverVest turns in strong 2014, eyes 2015 growth

By:  Brian Feldt, Reporter St. Louis Business Journal December 26, 2014   RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology. This year may be its best campaign yet. RiverVest exited a dozen portfolio companies since 2011, returning $290.5 million to the firm, or 3.5 times the dollars invested in those companies ($83 million).  Read more. Source: St. Louis Business...

read more

Otonomy Provides Corporate and Product Pipeline Update

SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced an update on its corporate activities and product pipeline.   Corporate and Product Pipeline Update • NDA Submission for AuriPro™ planned for 1Q2015: Preparation of the New Drug Application (NDA) for AuriPro is in process, and incorporates feedback received from a...

read more

Otonomy Provides Corporate and Product Pipeline Update

SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced an update on its corporate activities and product pipeline. Corporate and Product Pipeline Update • NDA Submission for AuriPro™ planned for 1Q2015: Preparation of the New Drug Application (NDA) for AuriPro is in process, and incorporates feedback received from a Pre-NDA...

read more

Otonomy Files Registration Statement for Proposed Follow-on Public Offering

SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of $75 million of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. In...

read more

Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere’s Disease

SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company has achieved target enrollment in its Phase 2b clinical trial of OTO-104 in patients with Ménière’s disease. This prospective, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of OTO-104 for the treatment of...

read more

ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine

ZS-9 Normalizes 98 Percent of Patients Within 48 Hours and a High Proportion of Patients Who Continued on ZS-9 Maintained Normokalemia COPPELL, Texas, Nov. 21, 2014 (GLOBE NEWSWIRE) — ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM). ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind,...

read more

ZS Pharma Presents Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA

Coppell, Texas – November 17, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions. HARMONIZE is the second positive Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, a life threatening condition characterized by abnormally high...

read more

Kindred Announces Definitive Agreement to Acquire Centerre Healthcare

Creating One of Nation’s Largest Networks of Inpatient Rehabilitation Hospitals and Significantly Expanding Kindred’s Continuum of Services Kindred to Establish New Growth Platform, Kindred Hospital Rehabilitation Services, Upon Closing of the Transaction November 12, 2014 08:00 AM Eastern Standard Time LOUISVILLE, Ky.–(BUSINESS WIRE)–Kindred Healthcare, Inc. (“Kindred” or the “Company”) (NYSE:KND), the nation’s largest provider of integrated post-acute care and rehabilitation, today announced that it has signed a...

read more

Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus

SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, and Ipsen (Euronext:IPN) (ADR:IPSEY), a global specialty-driven pharmaceutical company, today announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen’s gacyclidine data in the development and registration of OTO-311. OTO-311 is...

read more